Veena Venugopalan

826 total citations
34 papers, 521 citations indexed

About

Veena Venugopalan is a scholar working on Pharmacology, Epidemiology and Applied Microbiology and Biotechnology. According to data from OpenAlex, Veena Venugopalan has authored 34 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pharmacology, 16 papers in Epidemiology and 9 papers in Applied Microbiology and Biotechnology. Recurrent topics in Veena Venugopalan's work include Antibiotics Pharmacokinetics and Efficacy (19 papers), Pneumonia and Respiratory Infections (10 papers) and Antibiotic Use and Resistance (9 papers). Veena Venugopalan is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (19 papers), Pneumonia and Respiratory Infections (10 papers) and Antibiotic Use and Resistance (9 papers). Veena Venugopalan collaborates with scholars based in United States and United Kingdom. Veena Venugopalan's co-authors include Kimberly Shriner, Annie Wong‐Beringer, Kartikeya Cherabuddi, Kenneth Klinker, Charles A. Peloquin, Mohammad H. Al‐Shaer, Leonard Berkowitz, Levita Hidayat, Anthony M. Casapao and Marc H. Scheetz and has published in prestigious journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Emerging infectious diseases.

In The Last Decade

Veena Venugopalan

29 papers receiving 505 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Veena Venugopalan United States 12 203 148 135 124 115 34 521
Luigi Celani Italy 11 200 1.0× 352 2.4× 194 1.4× 125 1.0× 203 1.8× 25 802
Esther E Avendano United States 14 99 0.5× 180 1.2× 116 0.9× 148 1.2× 111 1.0× 36 728
Monica Licker Romania 15 77 0.4× 249 1.7× 181 1.3× 140 1.1× 133 1.2× 63 673
Thomas Lund Sørensen Denmark 11 73 0.4× 154 1.0× 127 0.9× 79 0.6× 107 0.9× 23 604
Sabrina Khan United States 8 135 0.7× 204 1.4× 161 1.2× 51 0.4× 166 1.4× 10 513
Marta Vallejo Spain 9 79 0.4× 212 1.4× 81 0.6× 93 0.8× 124 1.1× 14 660
Keite da Silva Nogueira Brazil 13 57 0.3× 252 1.7× 120 0.9× 76 0.6× 99 0.9× 55 588
Yasunao Wada Japan 11 134 0.7× 179 1.2× 87 0.6× 84 0.7× 65 0.6× 20 460
Ulrich Stab Jensen Denmark 15 45 0.2× 101 0.7× 156 1.2× 113 0.9× 177 1.5× 25 702
Kirati Kengkla Thailand 11 88 0.4× 200 1.4× 111 0.8× 110 0.9× 61 0.5× 26 500

Countries citing papers authored by Veena Venugopalan

Since Specialization
Citations

This map shows the geographic impact of Veena Venugopalan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veena Venugopalan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veena Venugopalan more than expected).

Fields of papers citing papers by Veena Venugopalan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veena Venugopalan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veena Venugopalan. The network helps show where Veena Venugopalan may publish in the future.

Co-authorship network of co-authors of Veena Venugopalan

This figure shows the co-authorship network connecting the top 25 collaborators of Veena Venugopalan. A scholar is included among the top collaborators of Veena Venugopalan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veena Venugopalan. Veena Venugopalan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Childs‐Kean, Lindsey M., et al.. (2024). The OPAT opportunity for beta-lactam individualization. SHILAP Revista de lepidopterología. 4(1). e115–e115.
2.
Prins, Cindy, Jamie L. Pomeranz, Kartikeya Cherabuddi, et al.. (2024). Infection prevention and control in long-term care facilities in Florida: A needs assessment survey. American Journal of Infection Control. 53(2). 210–221.
3.
Venugopalan, Veena, et al.. (2024). Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV. International Journal of STD & AIDS. 35(8). 651–653. 5 indexed citations
4.
Taylor, James R., et al.. (2024). Implementation of standard setting for high-stakes objective structured clinical examinations. Currents in Pharmacy Teaching and Learning. 16(6). 465–468. 2 indexed citations
5.
Venugopalan, Veena, et al.. (2023). Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population‐based propensity score‐matched cohort study. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 43(9). 883–893. 9 indexed citations
6.
Venugopalan, Veena, et al.. (2023). Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy. JAC-Antimicrobial Resistance. 6(1). dlad157–dlad157. 4 indexed citations
7.
Chang, Jack, Jiajun Liu, Mohammad H. Al‐Shaer, et al.. (2023). Making the case for precision dosing: visualizing the variability of cefepime exposures in critically ill adults. Journal of Antimicrobial Chemotherapy. 78(9). 2170–2174. 3 indexed citations
8.
Al‐Shaer, Mohammad H., et al.. (2023). Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients. Pulmonary Pharmacology & Therapeutics. 84. 102271–102271. 5 indexed citations
9.
Allen, John M., et al.. (2023). Exploring Trends in Social Vulnerability for Pharmacy Students at a Large Public University. American Journal of Pharmaceutical Education. 87(12). 100551–100551. 1 indexed citations
10.
Venugopalan, Veena, et al.. (2023). Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI). JAC-Antimicrobial Resistance. 5(2). dlad021–dlad021. 7 indexed citations
11.
12.
Venugopalan, Veena, et al.. (2020). Evaluation of Susceptibility Patterns in Uropathogens and Empiric Antibiotic Therapy in the Emergency Department. Hospital Pharmacy. 56(6). 745–750.
13.
Casapao, Anthony M., et al.. (2020). An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Clinical Therapeutics. 42(4). 692–702. 21 indexed citations
14.
Allen, John M., et al.. (2020). Impact of supplemental individual verbal defense on confidence, engagement, and performance in a team-based learning therapeutics course. Currents in Pharmacy Teaching and Learning. 13(2). 152–158. 2 indexed citations
15.
Venugopalan, Veena, et al.. (2018). Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms. International Journal of Antimicrobial Agents. 52(5). 719–723. 16 indexed citations
16.
Hidayat, Levita, et al.. (2018). Use of an Anti-Infective Medication Review Process at Hospital Discharge to Identify Medication Errors and Optimize Therapy. Journal of Pharmacy Practice. 32(5). 488–492. 3 indexed citations
17.
Hidayat, Levita, et al.. (2016). Management of skin and soft-tissue infections at a community teaching hospital using a severity-of-illness tool. Journal of Antimicrobial Chemotherapy. 71(11). 3268–3275. 11 indexed citations
18.
19.
Bias, Tiffany E., et al.. (2014). Incidence of Antiretroviral Drug Interactions During Hospital Course. Journal of Pharmacy Technology. 30(2). 48–53. 9 indexed citations
20.
Venugopalan, Veena, Kimberly Shriner, & Annie Wong‐Beringer. (2010). Regulatory Oversight and Safety of Probiotic Use. Emerging infectious diseases. 16(11). 1661–1665. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luigi Celani Breakdown of academic impact, for papers by Esther E Avendano Breakdown of academic impact, for papers by Monica Licker Breakdown of academic impact, for papers by Thomas Lund Sørensen Breakdown of academic impact, for papers by Sabrina Khan Breakdown of academic impact, for papers by Marta Vallejo Breakdown of academic impact, for papers by Keite da Silva Nogueira Breakdown of academic impact, for papers by Yasunao Wada Breakdown of academic impact, for papers by Ulrich Stab Jensen Breakdown of academic impact, for papers by Kirati Kengkla
Rankless by CCL
2026